Invivyd (IVVD) vs Lineage Cell Therapeutics (LCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lineage Cell Therapeutics (LCTX) has outperformed Invivyd (IVVD) over the past year, losing 45.2% versus a loss of 55.3%. Over five years, LCTX leads with a -59.7% price change compared with -97.8% for IVVD. Lineage Cell Therapeutics is the larger company by market cap ($235.9 million vs $204.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IVVD | LCTX |
|---|---|---|
| Share price | $0.6924 | $0.9328 |
| Market cap | $204.09M | $235.91M |
| 1-day change | -4.97% | -1.56% |
| YTD return | -70.50% | -43.26% |
| 1-year return | -55.30% | -45.23% |
| 5-year return | -97.75% | -59.68% |
| EPS (TTM) | $-0.33 | $-0.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.07 | $2.09 |
| 52-week low | $0.528 | $0.88 |
| Distance from 52-week high | -77.45% | -55.37% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1344.25% | +489.62% |
| Average volume | 4.78M | 1.15M |
| Shares outstanding | 294.76M | 252.91M |
| Employees | 122 | 72 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LCTX has outperformed IVVD by 10.1 percentage points over the past year.
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
About Lineage Cell Therapeutics
LCTX stock →Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 72 employees
IVVD vs LCTX FAQ
Which is bigger, Invivyd or Lineage Cell Therapeutics?
Lineage Cell Therapeutics (LCTX) is larger, with a market capitalization of $235.91M compared with $204.09M for Invivyd (IVVD).
Which stock has performed better over the past year, IVVD or LCTX?
LCTX returned -45.23% over the past 12 months, compared with -55.30% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Invivyd and Lineage Cell Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.